The curious case of clioquinol

[1] Treatment with a copper-zinc chelator markedly and rapidly inhibits β-amyloid accumulation in Alzheimer's disease transgenic mice [J]. NEURON, 2001, 30 (03) : 665 - 676

[2] Anticancer activity of the antibiotic clioquinol [J]. CANCER RESEARCH, 2005, 65 (08) : 3389 - 3395

[3] Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: A novel therapy for Parkinson's disease [J]. NEURON, 2003, 37 (06) : 899 - 909

[4] Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial (vol 7, pg 779, 2008) [J]. LANCET NEUROLOGY, 2009, 8 (11) : 981 - 981

[5] NAKAE K, 1973, LANCET, V1, P171

[6] Clioquinol down-regulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington's disease mouse model [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (33) : 11840 - 11845

[7] Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Aβ amyloid deposition and toxicity in Alzheimer disease -: A pilot phase 2 clinical trial [J]. ARCHIVES OF NEUROLOGY, 2003, 60 (12) : 1685 - 1691

[8] SCHAUMBURG H, 2000, EXPT CLIN NEUROTOXIC, P395

[9] SHIGEMATSU I, 1975, JPN J MED SCI BIOL, V28, P23

[10] The Anti-neurodegeneration Drug Clioquinol Inhibits the Aging-associated Protein CLK-1 [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2009, 284 (01) : 314 - 323

[1] Treatment with a copper-zinc chelator markedly and rapidly inhibits β-amyloid accumulation in Alzheimer's disease transgenic mice [J]. NEURON, 2001, 30 (03) : 665 - 676

[2] Anticancer activity of the antibiotic clioquinol [J]. CANCER RESEARCH, 2005, 65 (08) : 3389 - 3395

[3] Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: A novel therapy for Parkinson's disease [J]. NEURON, 2003, 37 (06) : 899 - 909

[4] Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial (vol 7, pg 779, 2008) [J]. LANCET NEUROLOGY, 2009, 8 (11) : 981 - 981

[5] NAKAE K, 1973, LANCET, V1, P171

[6] Clioquinol down-regulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington's disease mouse model [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (33) : 11840 - 11845

[7] Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Aβ amyloid deposition and toxicity in Alzheimer disease -: A pilot phase 2 clinical trial [J]. ARCHIVES OF NEUROLOGY, 2003, 60 (12) : 1685 - 1691

[8] SCHAUMBURG H, 2000, EXPT CLIN NEUROTOXIC, P395

[9] SHIGEMATSU I, 1975, JPN J MED SCI BIOL, V28, P23

[10] The Anti-neurodegeneration Drug Clioquinol Inhibits the Aging-associated Protein CLK-1 [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2009, 284 (01) : 314 - 323